Here are the DEF 14A proxy statements from NRX Pharmaceuticals, Inc. Warrant (NRXPW) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow NRXPW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NRXPW filings page.
NRx Pharmaceuticals is asking stockholders to vote on key governance and compensation items at its 2025 Annual Meeting, to be held virtually on March 23, 2026. Holders of 31,872,340 common shares as of February 12, 2026 can vote.
Proposals include electing two Class I directors (Chaim Hurvitz and Michael Taylor) to terms running to the 2028 meeting, approving an amendment to the 2021 Omnibus Incentive Plan, ratifying Weinberg & Company, P.A. as independent auditor for 2025, and a non-binding advisory vote on executive pay. The plan amendment would increase the annual “evergreen” share reserve to the lesser of 3,187,234 shares, 5% of fully diluted shares outstanding, or a smaller amount set by the Board.